In a continued evolution for the incorporation of biomarkers, a study by Babu et al, using PBR‐28 as a PET marker of neuroinflammation combined with neurofilament light chain (NfL) as a proposed biomarker of ALS disease progression, completed an open‐label study of ibudilast that failed to show any effect on these markers.40 This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.